ইস্রায়েল - হিব্রু - Ministry of Health

גרוברמן שיווק -

ইস্রায়েল - হিব্রু - Ministry of Health

novartis israel ltd - ciprofloxacin as hydrochloride - תמיסה - ciprofloxacin as hydrochloride 3 mg/ml - ciprofloxacin - ciprofloxacin - corneal ulcers and conjunctivitis caused by susceptible gram positive and gram negative microorganisms for adults and pediatric patients above the age of 1 year. for localized or diffuse otitis externa accompanied by a strong inflammatory reaction and of which the strains are susceptible to ciprofloxacin, and for the acute flare-up of a chronic otitis media. in this case, a mucopurulent secretion comes through the perforated eardrum. pseudomonas aeruginosa is one of the organisms most likely to be found in this case. also in other infections of the ear in which pseudomonas aeruginosa and/or other susceptible strains may be demonstrated or suspected (for example with suppurating tympanic tubes), ciloxan can be used under the strict supervision of an ear specialist. it must be understood that this is not a routine treatment and that improper use must be avoided.

ইস্রায়েল - হিব্রু - Ministry of Health

j-c healthcare ltd. - רופא - גנרטור לשמוש בתהליכי פיזיולוגיה

ইস্রায়েল - হিব্রু - Ministry of Health

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 50 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

ইস্রায়েল - হিব্রু - Ministry of Health

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 100 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

ইস্রায়েল - হিব্রু - Ministry of Health

novartis israel ltd - brinzolamide; timolol as maleate - תרחיף לעין - brinzolamide 10 mg/ml; timolol as maleate 5 mg/ml - timolol, combinations - timolol, combinations - decrease of intra-ocular pressure (iop) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient iop reduction.

ইস্রায়েল - হিব্রু - Ministry of Health

raz pharmaceutics ltd, israel - dopamine hydrochloride - תרכיז להכנת תמיסה לאינפוזיה - dopamine hydrochloride 40 mg / 1 ml - dopamine

ইস্রায়েল - হিব্রু - Ministry of Health

j-c health care ltd - decitabine - אבקה להכנת תמיסה מרוכזת לעירוי - decitabine 50 mg/vial - decitabine - decitabine - - dacogen is indicated for treatment of patients with myelodysplastic syndromes (mds) including prevviously treated and untreated, de novo and secondary mds of all french-american- british subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia ) and intermediate- 1, intermediate- 2, and high-risk international prognostic scoring system groups.- dacogen is indicated for the treatment of adult patients aged 65 years and above with newly diagnosed de novo or secondary acute myeloid leukaemia (aml), according to the world health organisation (who) classification, who are not candidates for standard induction chemotherapy

ইস্রায়েল - হিব্রু - Ministry of Health

padagis israel agencies ltd, israel - dextromethorphan hydrobromide; guaifenesin - סירופ - dextromethorphan hydrobromide 10 mg / 5 ml; guaifenesin 100 mg / 5 ml - dextromethorphan - dextromethorphan - for relief of cough and expecctorant.

ইস্রায়েল - হিব্রু - Ministry of Health

padagis israel agencies ltd, israel - dextromethorphan hydrobromide; guaifenesin - סירופ - dextromethorphan hydrobromide 10 mg / 5 ml; guaifenesin 100 mg / 5 ml - dextromethorphan - dextromethorphan - for relief of cough and expecctorant.